Novel Approaches and Targeted Therapies in AML
Session V of iwAL 2019 saw targeted therapies and novel approaches in AML discussed,
with e-learning webinars from Marina Konopleva, MD, Mark Levis, MD, PhD, Naval Daver, MD, Richard Stone, MD, and Torsten Haferlach, MD.
Various therapies came into focus, including MDM2 inhibitors, venetoclax-based therapy, FTL3+ targets, antibody-drug conjugates, liposomal formations, HDAC inhibitors and syk inhibition.
Dana-Farber Cancer Institute, Boston, MA
University of Texas MD Anderson Cancer Center, Houston, TX
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
University of Texas MD Anderson Cancer Center, Houston, TX
University of Texas MD Anderson Cancer Center, Houston, TX
Dana-Farber Cancer Institute, Boston, MA
Munich Leukemia Laboratory, Munich, Germany
Dana-Farber Cancer Institute, Boston, MA